Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation

Experimental Cell Research

Volumn 319, Issue 14, 2013, Pages 2166-2178

  Honma, Yuichi ^a   Harada, Masaru ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Apoptosis; Autophagy; Endoplasmic reticulum stress; Hepatocellular carcinoma; Necrosis

Indexed keywords

3 MA; ANTINEOPLASTIC AGENT; EPOXOMICIN; KERATIN; N ACETYLLEUCYLLEUCYLNORLEUCINAL; PROTEASOME INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL; MEDIATOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; UBIQUITINATION; UNFOLDED PROTEIN RESPONSE;

EID: 84880743543     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2013.05.023     Document Type: Article

References (46)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255.
2. Bruix J, Sherman M PracticE GUidelines committee, American association for the study of liver diseases. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
3. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat. Clin. Pract. Oncol. 2007, 4:424-432.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J SHARP Investigation study group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10:25-34.
6. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. BAY 43-9006 exhibits broad spectrum oral autitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
7. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66:11851-11858.
8. Wang Z, Wang M, Carr BI. Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells. J. Cell. Physiol. 2010, 224:559-565.
9. Kostova Z, Wolf DH. For whom the bell tolls: protein quality control of the endoplasmic reticulum and the ubiquitin-proteasome connection. Embo J. 2003, 22:2309-2317.
10. Adams J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 2004, 4:349-360.
11. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu. Rev. Pharmacol. Toxicol. 2006, 46:189-213.
12. Harada M, Kumemura H, Omary MB, Kawaguchi T, Maeyama N, Hanada S, Taniguchi E, Koga H, Suganuma T, Ueno T, Sata M. Proteasome inhibition induces inclusion bodies associated with intermediate filaments and fragmentation of the Golgi apparatus. Exp. Cell. Res. 2003, 288:60-69.
13. Harada M, Strnad P, Toivola DM, Omary MB. Autophagy modulates keratin-containing inclusion formation and apoptosis in cell culture in a context-dependent fashion. Exp. Cell Res. 2008, 314:1753-1764.
14. Harada M, Hanada S, Toivola DM, Ghori N, Omary MB. Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation. Hepatology 2008, 47:2026-2035.
15. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell. Biol. 2007, 8:519-529.
16. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J. Hepatol. 2011, 54:795-809.
17. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 2004, 306:990-995.
18. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
19. Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, Grant S, Dent P. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol. Cancer Ther. 2010, 9:2220-2231.
20. Ullén A, Farnebo M, Thyrell L, Mahmoudi S, Kharaziha P, Lennartsson L, Grandér D, Panaretakis T, Nilsson S. Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int. J. Oncol. 2010, 37:15-20.
21. Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res. 2011, 71:4955-4967.
22. Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int. J. Cancer 2012, 131:548-557.
23. Coulombe PA, Omary MB. 'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments. Curr. Opin. Cell. Biol. 2002, 14:110-122.
24. Ku NO, Omary MB. A disease- and phosphorylation-related nonmechanical function for keratin 8. J. Cell. Biol. 2006, 174:115-125.
25. Ku NO, Michie SA, Soetikno RM, Resurreccion EZ, Broome RL, Omary MB. Mutation of a major keratin phosphorylation site predispose to hepatotoxic injury in transgenic mice. J. Cell. Biol. 1998, 143:2023-2032.
26. Omary MB, Coulombe PA, McLean WH. Intermediate filament proteins and their associated diseases. N. Engl. J. Med. 2004, 351:2087-2100.
27. Toivola DM, Ku NO, Resurreccion EZ, Nelson DR, Wright TL, Omary MB. Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease. Hepatology 2004, 40:459-466.
28. Harada M, Strnad P, Resurreccion EZ, Ku NO, Omary MB. Keratin 18 overexpression but not phosphorylation or filament organization blocks mouse Mallory body formation. Hepatology 2007, 45:88-96.
29. Kwan R, Hanada S, Harada M, Strnad P, Li DH, Omary MB. Keratin 8 phosphorylation regulates its transamidation and hepatocyte Mallory-Denk body formation. Faseb J. 2012, 26:2318-2326.
30. Zatloukal K, French SW, Stumptner C, Strnad P, Harada M, Toivola DM, Cadrin M, Omary MB. From Mallory to Mallory-Denk bodies: what, how and why?. Exp. Cell. Res. 2007, 313:2033-2049.
31. Strnad P, Stumptner C, Zatloukal K, Denk H. Intermediate filament cytoskeleton of the liver in health and disease. Histochem. Cell. Biol. 2008, 129:735-749.
32. Kobayashi N, Miyazaki M, Fukaya K, Inoue Y, Sakaguchi M, Uemura T, Noguchi H, Kondo A, Tanaka N, Namba M. Transplantation of highly differentiated immortalized human hepatocytes to treat acute liver failure. Transplantation 2000, 69:202-207.
33. Ku NO, Toivola DM, Zhou Q, Tao GZ, Zhong B, Omary MB. Studying simple epithelial keratins in cells and tissues. Methods Cell. Biol. 2004, 78:489-517.
34. Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol. Cancer Ther. 2006, 5:2378-2387.
35. Ku NO, Liao J, Omary MB. Apoptosis generates stable fragments of human type I keratins. J. Biol. Chem. 1997, 272:33197-33203.
36. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. Embo J. 2000, 19:5720-5728.
37. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell 2010, 140:313-326.
38. Mizushima N, Yoshimori T, Ohsumi Y. The role of Atg proteins in autophagosome formation. Annu. Rev. Cell. Dev. Biol. 2011, 27:107-132.
39. Seglen PO, Gordon PB. 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc. Natl. Acad. Sci. 1982, 79:1889-1892.
40. Edinger AL, Thompson CB. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell. Biol. 2004, 16:663-669.
41. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell. Biol. 2005, 6:79-87.
42. Haglund K, Dikic I. Ubiquitylation and cell signaling. Embo J. 2005, 24:3353-3359.
43. 120 of Ubc2/Rad6 regulates ubiquitin-dependent N-end rule targeting by E3α/Ubr1. J. Biol. Chem. 2010, 285:41300-41309.
44. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999, 397:271-274.
45. Chamcheu JC, Siddiqui IA, Syed DN, Adhami VM, Liovic M, Mukhtar H. Keratin gene mutations in disorders of human skin and its appendages. Arch. Biochem. Biophys. 2011, 508:123-137.
46. Ku NO, Strnad P, Zhong BH, Tao GZ, Omary MB. Keratins let liver live: Mutations predispose to liver disease and crosslinking generates Mallory-Denk bodies. Hepatology 2007, 46:1639-1649.